Request a copy

Full Text

• Prieto-Garcia, E., Diaz-Garcia, C. V., Garcia-Ruiz, I. & Agullo-Ortuno, M. T. Epithelial-to-mesenchymal transition in tumor progression. Med. Oncol. 34, 122 (2017).
• Li, W. et al. Methylation-mediated silencing of microRNA-211 promotes cell growth and epithelial to mesenchymal transition through activation of the AKT/beta-catenin pathway in GBM. Oncotarget 8, 25167–25176 (2017).
• Li, Q. et al. KDM6B induces epithelial-mesenchymal transition and enhances clear cell renal cell carcinoma metastasis through the activation of SLUG. Int. J. Clin. Exp. Pathol. 8, 6334–6344 (2015).
• Yang, F. et al. SET8 promotes epithelial-mesenchymal transition and confers TWIST dual transcriptional activities. EMBO J. 31, 110–123 (2012).
• Gemmill, R. M. et al. ZEB1-responsive genes in non-small cell lung cancer. Cancer Lett. 300, 66–78 (2011).
• Yamauchi, Y. et al. Tumor necrosis factor-alpha enhances both epithelial-mesenchymal transition and cell contraction induced in A549 human alveolar epithelial cells by transforming growth factor-beta1. Exp. Lung Res. 36, 12–24 (2010).
• Kim, J., Kong, J., Chang, H., Kim, H. & Kim, A. EGF induces epithelial-mesenchymal transition through phospho-Smad2/3-Snail signaling pathway in breast cancer cells. Oncotarget 7, 85021–85032 (2016).
• Wu, Y. et al. Stabilization of snail by NF-kappaB is required for inflammation-induced cell migration and invasion. Cancer Cell 15, 416–428 (2009).
• Asgarova, A. et al. PD-L1 expression is regulated by both DNA methylation and NF-kB during EMT signaling in non-small cell lung carcinoma. Oncoimmunology 7, e1423170 (2018).
• Taddei, M. L., Giannoni, E., Comito, G. & Chiarugi, P. Microenvironment and tumor cell plasticity: an easy way out. Cancer Lett. 341, 80–96 (2013).
• Parker, J. S. et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J. Clin. Oncol. 27, 1160–1167 (2009).
• Serrano-Gomez, S. J., Maziveyi, M. & Alahari, S. K. Regulation of epithelial-mesenchymal transition through epigenetic and post-translational modifications. Mol. Cancer 15, 18 (2016).
• Mullen, A. C. et al. Master transcription factors determine cell-type-specific responses to TGF-beta signaling. Cell 147, 565–576 (2011).
• Du, L. et al. Transcriptome profiling reveals novel gene expression signatures and regulating transcription factors of TGFbeta-induced epithelial-to-mesenchymal transition. Cancer Med. 5, 1962–1972 (2016).
• Cieslik, M. et al. Epigenetic coordination of signaling pathways during the epithelial-mesenchymal transition. Epigenetics Chromatin 6, 28 (2013).
• Lang, Z. Q., Wu, Y. Q., Pan, X. B., Qu, G. M. & Zhang, T. G. The identification of multifocal breast cancer-associated long non-coding RNAs. Eur. Rev. Med. Pharmacol. Sci. 21, 5648–5654 (2017).
• Han, Y. et al. HOXA13 contributes to gastric carcinogenesis through DHRS2 interacting with MDM2 and confers 5-FU resistance by a p53-dependent pathway. Mol. Carcinog. 57, 722–734 (2018).
• Wang, M. et al. Large-scale association analysis in Asians identifies new susceptibility loci for prostate cancer. Nat. Commun. 6, 8469 (2015).
• Schneider, R. et al. Histone H3 lysine 4 methylation patterns in higher eukaryotic genes. Nat. Cell Biol. 6, 73–77 (2004).
• Kim, D. H. et al. Histone H3K27 trimethylation inhibits H3 binding and function of SET1-like H3K4 methyltransferase complexes. Mol. Cell. Biol. 33, 4936–4946 (2013).
• Lo, H. W. et al. Epidermal growth factor receptor cooperates with signal transducer and activator of transcription 3 to induce epithelial-mesenchymal transition in cancer cells via up-regulation of TWIST gene expression. Cancer Res. 67, 9066–9076 (2007).
• Bonnomet, A. et al. A dynamic in vivo model of epithelial-to-mesenchymal transitions in circulating tumor cells and metastases of breast cancer. Oncogene 31, 3741–3753 (2012).
• Cao, R. et al. Elevated expression of myosin X in tumours contributes to breast cancer aggressiveness and metastasis. Br. J. Cancer 111, 539–550 (2014).
• Duffy, M. J., McKiernan, E., O’Donovan, N. & McGowan, P. M. Role of ADAMs in cancer formation and progression. Clin. Cancer Res. 15, 1140–1144 (2009).
• Wang, X. et al. MiR-145 inhibits the epithelial-to-mesenchymal transition via targeting ADAM19 in human glioblastoma. Oncotarget 8, 92545–92554 (2017).
• Mi, H. et al. PANTHER version 11: expanded annotation data from Gene Ontology and Reactome pathways, and data analysis tool enhancements. Nucleic Acids Res. 45, D183–D189 (2017).
• Gnemmi, V. et al. MUC1 drives epithelial-mesenchymal transition in renal carcinoma through Wnt/beta-catenin pathway and interaction with SNAIL promoter. Cancer Lett. 346, 225–236 (2014).
• Chen, C., Khaleel, S. S., Huang, H. & Wu, C. H. Software for pre-processing Illumina next-generation sequencing short read sequences. Source Code Biol. Med. 9, 8 (2014).
• Zang, C. et al. A clustering approach for identification of enriched domains from histone modification ChIP-Seq data. Bioinformatics 25, 1952–1958 (2009).
• Huang, W., Loganantharaj, R., Schroeder, B., Fargo, D. & Li, L. PAVIS: a tool for Peak Annotation and Visualization. Bioinformatics 29, 3097–3099 (2013).
• Wang, S. et al. Target analysis by integration of transcriptome and ChIP-seq data with BETA. Nat. Protoc. 8, 2502–2515 (2013).
• Ramirez, F. et al. deepTools2: a next generation web server for deep-sequencing data analysis. Nucleic Acids Res. 44, W160–W165 (2016).
• Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA 102, 15545–15550 (2005).
• Herfs, M. et al. Proteomic signatures reveal a dualistic and clinically relevant classification of anal canal carcinoma. J. Pathol. 241, 522–533 (2017).
• Hubert, P. et al. Altered alpha-defensin 5 expression in cervical squamocolumnar junction: implication in the formation of a viral/tumour-permissive microenvironment. J. Pathol. 234, 464–477 (2014).